Diagnosing Vesicoureteric Reflux in Children by Direct Isotope Cystography and Contrast Enhanced Voiding Ultrasonography

2024-518974-15-01 Therapeutic use (Phase IV) Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic use (Phase IV)
Status Authorised, recruitment pending
Participants planned 100
Countries 1
Sites 1

Vesicoureteral reflux

Diagnostic accoracy of CEVUS in detecting vesicoureteral reflux

Key facts

Sponsor
Turku University Hospital
Participant type
Pediatric, Patients
Age range
0-17 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13], Diseases [C] - Male Urogenital Diseases [C12]
Decision date (initial)
2024-11-18
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518974-15-01
EudraCT number
2021-006371-42

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Diagnosis

Diagnostic accoracy of CEVUS in detecting vesicoureteral reflux

Conditions and MedDRA coding

Vesicoureteral reflux

Regulatory references

Plan to share IPD
No
EU CT numberTitleSponsor
2024-518974-15-00 Diagnosing Vesicoureteric Reflux in Children by Direct Isotope Cystography and Contrast Enhanced Voiding Ultrasonography Turku University Hospital

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 1

  1. under 6 years old patients who have had at least 2 culture positive urinary tract infections

Exclusion criteria 1

  1. abnormal bladder function posterior uretral valves

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

  1. Vesicoureteral reflux yes or no

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

SonoVue 8 microlitres/mL powder and solvent for dispersion for injection

PRD451459 · Product

Active substance
Sulfur Hexafluoride
Pharmaceutical form
DISPERSION FOR INJECTION
Route of administration
INTRAVESICAL USE
Max daily dose
0.2 % (V/V) percent volume/volume
Max total dose
0.2 % (V/V) percent volume/volume
Max treatment duration
1 Day(s)
Authorisation status
Authorised
ATC code
V08DA05 — SULFUR HEXAFLUORIDE
Marketing authorisation
EU/1/01/177/002
MA holder
BRACCO INTERNATIONAL BV
MA country
EU
Paediatric formulation
No
Orphan designation
No
Modified vs. Marketing Authorisation
No

Comparator 1

Ultra-TechneKow FM, 2,15–43,00 GBq, radionuklidigeneraattori

PRD5961924 · Product

Active substance
Technetium (99MTC)
Pharmaceutical form
SOLUTION FOR INJECTION
Route of administration
INTRAVESICAL USE
Max daily dose
40 MBq megabecquerel(s)
Max total dose
40 MBq megabecquerel(s)
Max treatment duration
1 Day(s)
Authorisation status
Authorised
ATC code
V09FX01 — TECHNETIUM (99MTC) PERTECHNETATE
Marketing authorisation
11275
MA holder
CURIUM NETHERLANDS B.V.
MA country
Finland
Paediatric formulation
No
Orphan designation
No
Modified vs. Marketing Authorisation
No

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Turku University Hospital

15 Total trials 6 Recruiting
Academic / Non-commercial
Sponsor organisation
Turku University Hospital
Address
Kiinamyllynkatu 4-8
City
Turku
Postcode
20520
Country
Finland

Scientific contact point

Organisation
Turku University Hospital
Contact name
Pediatric surgery

Public contact point

Organisation
Turku University Hospital
Contact name
Pediatric surgery

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Authorised, recruitment pending 100 1
Rest of world 0

Investigational sites

Finland

1 site · Authorised, recruitment pending
Turku University Hospital
Pediatric Surgery, Kiinamyllynkatu 4-8, 20520, Turku

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 6 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

TypeTitleVersion
Protocol (for publication) Tutkimussuunnitelma 1
Recruitment arrangements (for publication) Tiedote tutkittavan vanhemmalle 1
Subject information and informed consent form (for publication) Suostumuslomake 1
Subject information and informed consent form (for publication) Tiedote tutkittavan vanhemmalle 1
Summary of Product Characteristics (SmPC) (for publication) valmisteyhteenveto_Generaattori_Ultra-TechneKow 1
Summary of Product Characteristics (SmPC) (for publication) valmisteyhteenvetoSonoVue SPC 1

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-04 Finland Acceptable
2024-11-15
2024-11-18